Hyaluronidase & CAR-T Development Service for Solid Tumor Penetration

The immunosuppressive and physically dense tumor microenvironment (TME) remains a major obstacle to CAR-T efficacy in solid tumors, often leading to poor cell infiltration and therapeutic resistance. Creative Biolabs' Hyaluronidase & CAR-T Development Service for Solid Tumor Penetration is designed to enzymatically remodel the extracellular matrix. By integrating engineered hyaluronidase via genetic expression or surface conjugation, we enhance CAR-T penetration into tumor cores and disrupt the HA-rich barrier. Our approach not only improves T cell mobility and localized antitumor activity but also supports sustained tumor suppression and measurable regression, providing a strategy to overcome stromal resistance.

Introduction

Hyaluronidase (HAase) is encapsulated within stimuli-responsive nanogels and conjugated to the surface of CAR-T cells via metabolic oligosaccharide engineering and click chemistry. This design enables its co-migration with T cells into deep tumor regions, where it is selectively released in the high-reactive-oxygen-species (ROS) tumor microenvironment to degrade the dense extracellular matrix (ECM). This integrated approach not only overcomes the vascular confinement typical of conventional nanotherapeutics but also significantly improves T cell penetration and cytotoxicity in solid tumors, offering a pivotal strategy to counteract immunosuppressive barriers within the TME.

Fig.1 Enhancing solid tumor penetration with hyaluronidase-enhanced CAR-T cells.

Hyaluronidase & CAR-T Development Service for Solid Tumor Penetration at Creative Biolabs

Creative Biolabs' Hyaluronidase & CAR-T Development Service for Solid Tumor Penetration overcomes the dense extracellular matrix barrier in solid tumors. By enzymatically degrading hyaluronan, our approach significantly enhances T cell infiltration and tumor penetration, substantially improving antitumor efficacy for solid tumor immunotherapy.

What We Can Offer

We offer genetically engineered HAase-secreting CAR-T cells for continuous matrix degradation, bio-orthogonal surface-armored T cells for immediate enzymatic activity, and inducible systems for spatiotemporally controlled HAase delivery, enabling optimal tumor penetration and customized therapeutic solutions.

Our Service Process

Required Starting Materials:

• Target Antigen Sequence: The specific sequence or detailed structural data for the tumor-associated antigen targeted by the CAR.
• CAR Structure/Vector: Existing CAR construct design, or the target specifications needed for us to design and synthesize the CAR vector (e.g., scFv sequence, co-stimulatory domains).
• T Cell Source: Detailed requirements for the starting material, typically human Peripheral Blood Mononuclear Cells (PBMCs) or specific T cell subsets.

Key steps:

Final Deliverables:

• Comprehensive Data Package: A full report including raw data and analysis for all QC, functional, and in vivo efficacy assays.
• Final CAR-T Product: Cryopreserved and validated CAR-T cell.
• Optimized Vector/Conjugation Protocol: The validated, ready-to-use vector for future large-scale manufacturing.

Key Advantages

• Proprietary Functional Validation: Gain a competitive edge with exclusive access to our advanced 3D HA-rich TME penetration assays and comprehensive analytical tools. We accurately quantify T cell motility and confirm HAase enzymatic activity.
• Custom Strategy Development: We don't use a one-size-fits-all approach. We provide customized selection and optimization for your TME-clearing strategy, choosing between stable genetic expression, biological modification, or nanogel-mediated delivery of HAase to ensure the optimal solution for your specific tumor indication and T cell platform.

FAQ

Why Choose Us?

Creative Biolabs is a recognized leader in cell therapy innovation, with decades of experience in complex protein and cell engineering. Our competitive advantage lies in our multifaceted approach to TME modulation, which moves beyond standard genetic engineering to encompass cutting-edge nanotechnology and chemical conjugation methods.

Customer Reviews

"Using Creative Biolabs' Hyaluronidase-Armed CAR-T Service in our research has significantly improved the predictability of our pre-clinical studies. Their 3D HA matrix assay provided conclusive evidence that their engineered cells infiltrated two times faster than our control cells, allowing us to confidently advance to in vivo models." Dr. M**uel, Senior Research.

"We needed a rapid, non-genetic method to modify our established CAR-T platform. Creative Biolabs' click chemistry linkage of HAase was incredibly efficient, providing rapid, high-yield cell surface modification that saved us three months of vector optimization time. The resulting cells showed a demonstrable increase in target-zone residency." J**son B., Director of Cell Therapy Development.

"The ability to arm our therapeutic T cells with a combination of Hyaluronidase and an α-PDL1 blocker was transformative. Their engineering strategy allowed us to simultaneously address the physical barrier and the immunosuppressive signaling, leading to an unprecedented, synergistic effect in our refractory lung tumor model." K**lie L., Head of Oncology R&D.

How to Contact Us?

To learn more about how our Hyaluronidase & CAR-T Development Service can transform your solid tumor immunotherapy pipeline, please reach out to our expert team.